Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study

In vitro activity of doripenem and comparator antimicrobial agents was evaluated against Gram-negative bacilli recently isolated from Brazilian private hospitals that were enrolled in the INVITA-A-DORI Brazilian Study. A total of 805 unique Gram-negative bacilli were collected from patients hospitalized at 18 medical centers between May/08 and March/09. Each hospital was asked to submit 50 single Gram-negative bacilli isolated from blood, lower respiratory tract or intraabdominal secretions. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using Clinical Laboratory Standards Institute (CLSI) microdilution method at a central laboratory. CLSI M100-S21 (2011) or US-FDA package insert criteria (tigecycline) was used for interpretation of the antimicrobial susceptibility results. Doripenem was as active as meropenem and more active than imipenem against E. coli and K. pneumoniae isolates. A total of 50.0% of Enterobacter spp. isolates were resistant to ceftazidime but 85.7% of them were inhibited at doripenem MICs < 1 µg/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MIC50/90, < 0.5/1 µg/mL) and P. aeruginosa (MIC50/90, 1/2 µg/mL). Although high rates of imipenem (53.1%) and meropenem (44.5%) resistance were detected among P. aeruginosa, doripenem showed MIC50 of 16 µg/mL against imipenem-resistant P. aeruginosa and inhibited a greater number of imipenem-resistant P. aeruginosa (10.5%) at MIC values of < 4 µg/mL than did meropenem (0.0%). In this study, doripenem showed similar in vitro activity to that of meropenem and retained some activity against imipenem-resistant P. aeruginosa isolated from Brazilian medical centers.

Saved in:
Bibliographic Details
Main Authors: Gales,Ana Cristina, Azevedo,Heber D, Cereda,Rosângela Ferraz, Girardello,Raquel, Xavier,Danilo Elias
Format: Digital revista
Language:English
Published: Brazilian Society of Infectious Diseases 2011
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000600003
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1413-86702011000600003
record_format ojs
spelling oai:scielo:S1413-867020110006000032012-01-04Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian studyGales,Ana CristinaAzevedo,Heber DCereda,Rosângela FerrazGirardello,RaquelXavier,Danilo Elias carbapenems Gram-negative bacteria Brazil In vitro activity of doripenem and comparator antimicrobial agents was evaluated against Gram-negative bacilli recently isolated from Brazilian private hospitals that were enrolled in the INVITA-A-DORI Brazilian Study. A total of 805 unique Gram-negative bacilli were collected from patients hospitalized at 18 medical centers between May/08 and March/09. Each hospital was asked to submit 50 single Gram-negative bacilli isolated from blood, lower respiratory tract or intraabdominal secretions. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using Clinical Laboratory Standards Institute (CLSI) microdilution method at a central laboratory. CLSI M100-S21 (2011) or US-FDA package insert criteria (tigecycline) was used for interpretation of the antimicrobial susceptibility results. Doripenem was as active as meropenem and more active than imipenem against E. coli and K. pneumoniae isolates. A total of 50.0% of Enterobacter spp. isolates were resistant to ceftazidime but 85.7% of them were inhibited at doripenem MICs < 1 µg/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MIC50/90, < 0.5/1 µg/mL) and P. aeruginosa (MIC50/90, 1/2 µg/mL). Although high rates of imipenem (53.1%) and meropenem (44.5%) resistance were detected among P. aeruginosa, doripenem showed MIC50 of 16 µg/mL against imipenem-resistant P. aeruginosa and inhibited a greater number of imipenem-resistant P. aeruginosa (10.5%) at MIC values of < 4 µg/mL than did meropenem (0.0%). In this study, doripenem showed similar in vitro activity to that of meropenem and retained some activity against imipenem-resistant P. aeruginosa isolated from Brazilian medical centers.info:eu-repo/semantics/openAccessBrazilian Society of Infectious DiseasesBrazilian Journal of Infectious Diseases v.15 n.6 20112011-12-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000600003en10.1590/S1413-86702011000600003
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Gales,Ana Cristina
Azevedo,Heber D
Cereda,Rosângela Ferraz
Girardello,Raquel
Xavier,Danilo Elias
spellingShingle Gales,Ana Cristina
Azevedo,Heber D
Cereda,Rosângela Ferraz
Girardello,Raquel
Xavier,Danilo Elias
Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study
author_facet Gales,Ana Cristina
Azevedo,Heber D
Cereda,Rosângela Ferraz
Girardello,Raquel
Xavier,Danilo Elias
author_sort Gales,Ana Cristina
title Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study
title_short Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study
title_full Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study
title_fullStr Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study
title_full_unstemmed Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study
title_sort antimicrobial activity of doripenem against gram-negative pathogens: results from invita-a-dori brazilian study
description In vitro activity of doripenem and comparator antimicrobial agents was evaluated against Gram-negative bacilli recently isolated from Brazilian private hospitals that were enrolled in the INVITA-A-DORI Brazilian Study. A total of 805 unique Gram-negative bacilli were collected from patients hospitalized at 18 medical centers between May/08 and March/09. Each hospital was asked to submit 50 single Gram-negative bacilli isolated from blood, lower respiratory tract or intraabdominal secretions. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using Clinical Laboratory Standards Institute (CLSI) microdilution method at a central laboratory. CLSI M100-S21 (2011) or US-FDA package insert criteria (tigecycline) was used for interpretation of the antimicrobial susceptibility results. Doripenem was as active as meropenem and more active than imipenem against E. coli and K. pneumoniae isolates. A total of 50.0% of Enterobacter spp. isolates were resistant to ceftazidime but 85.7% of them were inhibited at doripenem MICs < 1 µg/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MIC50/90, < 0.5/1 µg/mL) and P. aeruginosa (MIC50/90, 1/2 µg/mL). Although high rates of imipenem (53.1%) and meropenem (44.5%) resistance were detected among P. aeruginosa, doripenem showed MIC50 of 16 µg/mL against imipenem-resistant P. aeruginosa and inhibited a greater number of imipenem-resistant P. aeruginosa (10.5%) at MIC values of < 4 µg/mL than did meropenem (0.0%). In this study, doripenem showed similar in vitro activity to that of meropenem and retained some activity against imipenem-resistant P. aeruginosa isolated from Brazilian medical centers.
publisher Brazilian Society of Infectious Diseases
publishDate 2011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000600003
work_keys_str_mv AT galesanacristina antimicrobialactivityofdoripenemagainstgramnegativepathogensresultsfrominvitaadoribrazilianstudy
AT azevedoheberd antimicrobialactivityofdoripenemagainstgramnegativepathogensresultsfrominvitaadoribrazilianstudy
AT ceredarosangelaferraz antimicrobialactivityofdoripenemagainstgramnegativepathogensresultsfrominvitaadoribrazilianstudy
AT girardelloraquel antimicrobialactivityofdoripenemagainstgramnegativepathogensresultsfrominvitaadoribrazilianstudy
AT xavierdaniloelias antimicrobialactivityofdoripenemagainstgramnegativepathogensresultsfrominvitaadoribrazilianstudy
_version_ 1756416436104855552